Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Algard is a brand of over-the-counter (OTC) ophthalmic solutions developed and marketed by Rohto Pharmaceutical, primarily indicated for the relief of symptoms associated with allergic conjunctivitis, such as eye itching, redness, and swelling caused by pollen, house dust, or other allergens. The product line includes various formulations, typically combining mast cell stabilizers (e.g., sodium cromoglicate), antihistamines (e.g., chlorpheniramine maleate), and vasoconstrictors (e.g., tetryzoline hydrochloride) or anti-inflammatory agents (e.g., pranoprofen, dipotassium glycyrrhizinate). It is one of the leading allergy eye drop brands in Japan, with specific versions tailored for contact lens users and those requiring high-potency relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Algard.